KAI Research management has implemented the following precautionary measures in response to the COVID-19 pandemic:
Team Lead Mapping:
We have a complete mapping of both full-time as well as contract resources to identify those in regions at risk, and will trigger precautionary and contingency backup measures for continuity of services, based on the extent of risk alert.
Risk Management Plan:
We have identified and initiated as appropriate, approvals for staff to work from home, including the period for which such policy will be in effect. Multi-disciplinary BCP teams are continuously in touch with stakeholders, and are prepared to provide required support for both employee welfare as well as customer delivery requirements, to the extent possible.
Travel plans have been rearranged, and teleconferencing is the preferred channel of engagement, even for customer interactions during this period. Separate travel advisories have been issued through respective location heads.
KAI Research is now a part of Navitas Life Sciences
Supporting Clinical Research for the Warfighter
Bringing Focused Ultrasound Treatment Options to Patients
We are a full-service contract research organization (CRO) and health research company. Since 1986, we’ve helped pharmaceutical, academic, and federal clients bring innovative drug treatments and other interventions to market.
The numerous stakeholders involved in clinical research (e.g., patients, volunteers, investigators, sponsors, patient advocacy groups) can all agree that data sharing is essential, but it’s hardly routine as a current part of the clinical trial lifecycle. To address the various challenges and barriers related to sharing of clinical trial data, the Institute of Medicine (IOM)
Work with us. Contact us to learn how we can find the right solutions for all of your clinical research needs.
Click edit button to change this code.